ВестникНОМУС
.
Сборникматериалов
конкурса
литературных
обзоров
-2012
158
19.
Goodwin AK, Griffiths RR, Brown PR, Froestl W, Jakobs C, Gibson
KM, et al. Chronic intragastric administration of gamma-butyrolactone produces
physical dependence inbaboons // Psychopharmacology. 2006.- 189:P.71–82
20.
Heard K, Bebarta V.S. Reliability of the Glasgow
с
oma scale for the
emergency departmentevaluation of poisoned patients // Hum. Exp. Toxicol. 2004. −
Vol.23,
№
4. −P. 197-200
21.
Kim SY, Anderson IB, Dyer JE, Barker JC, Blanc PD. High-risk
behaviors and hospitalizations among gamma hydroxybutyrate (GHB) users // Am J
DrugAlcohol Abuse. 2007.-33:P.429–438.
22.
Koek W, Khanal M, France CP. Synergistic interactions between ‘club
drugs’: gamma-hydroxybutyrate and phencyclidine enhance each other’s
discriminative stimulus effects // BehavPharmacol. 2007.- 18: P.807–810.
23.
Maxwell Jane Carlisle «The response to club drug use», CurrOpin
Psychiatry16:000–000. 2003, LippincottWilliams&Wilkins
24.
Raybon JJ, Boje KMK. Pharmacokinetics and pharmacodynamics of
gamma-hydroxybutyric acid during tolerance in rats: effects of extracellular
dopamine. J PharmacolExpTher.2007.-320: P.1252–1260.
25.
Varela M, Nogué S, Orós M, Miró O. Gamma hydroxybutyrate use for
sexual assault. EmergMed J.2004.-21:P/255–256.
26.
Wood D.M., Warren-Gash C., Ashraf T., Greene S.L., Shather Z.,
Trivedy C., Clarke S., Ramsey J., Holt D.W. and Dargan P.I. «Medical and legal
confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-
butyrolactone (GBL) and 1,4-butanediol (1,4BD)», Q JMed2008.- 101: P. 23–29.
27.
WouterKoek,Lawrence P. Carter. Behavioral Analyses of GHB: Receptor
Mechanisms. PharmacolTher.-2009 January. - 121(1): P.100–114.
28.
/
Метаболические
_
препараты
29.
30.
СоболеваСветланаАнатольевна
,
студентка
2
курса
212
группы
лечебногофакультета
Митохондриальныецитопатииилизосомные болезни
накопления
РЕЗЮМЕ
